No direct effects of erythropoietin beta on a head and neck squamous cell carcinoma cell line which is growth stimulated in vivo

Acta Oncologica

Volumn 48, Issue 7, 2009, Pages 1062-1069

  Sasaki, Yutaka ^a,b   Kjellén, Elisabeth ^a   Mineta, Hiroyuki ^b   Wennerberg, Johan ^a   Ekblad, Lars ^a  

^a LUND UNIVERSITY   (Sweden)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ERYTHROPOIETIN RECEPTOR; RECOMBINANT ERYTHROPOIETIN;

ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER THERAPY; CARCINOMA CELL; CELL GROWTH; CELL MIGRATION; CELL STRESS; CONTROLLED STUDY; GROWTH STIMULATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HYPOXIA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; STROMA CELL; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR GROWTH; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING; WOUND HEALING; XENOGRAFT;

ANEMIA; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ERYTHROPOIETIN, RECOMBINANT; HEAD AND NECK NEOPLASMS; HUMANS; PROGNOSIS; RECEPTORS, ERYTHROPOIETIN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 70350060348     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860902913553     Document Type: Article

References (25)

1. Henke M, Laszig R, Rübe C, Schäfer U, Haase K-D, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003;/362:/1255-60.
2. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 2005;/23:/ 5960-5972
3. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 2008;/67:/39-61.
4. Melosky BL. Erythropoiesis-stimulating agents: Benefits and risks in supportive care of cancer. Curr Oncol 2008;/15:/ S10-5.
5. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW. Erythropoietin biology in cancer. Clin Cancer Res 2006;/12:/332-9.
6. Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG. Expression and function of erythropoietin receptors in tumors: Implications for the use of erythropoiesis- stimulating agents in cancer patients. Cancer 2007;/110:/ 477-488
7. Mohyeldin A, Lu H, Dalgard C, Lai SY, Cohen N, Acs G, et al. Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia 2005;/7:/537-43.
8. Lai SY, Childs EE, Xi S, Coppelli FM, Gooding WE, Wells A, et al. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 2005;/24:/4442-9.
9. LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Ze, Hall C, et al. Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther 2006;/5:/347-55.
10. Elliott S, Busse L, Bass MB, Lu H, Sarosi I, Sinclair AM, et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006;/107:/1892-5. (Pubitemid 43289368)
11. Henke M, Mattern D, Pepe M, Bezay C, Weissenberger C, Werner M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006;/24:/ 4708-4713 (Pubitemid 46630934)
12. Agarwal N, Gordeuk VR, Prchal JT. Are erythropoietin receptors expressed in tumors? Facts and fiction-more careful studies are needed. J Clin Oncol 2007;/25:/1813-4.
13. Della Ragione F, Cucciolla V, Borriello A, Oliva A, Perrotta S. Erythropoietin receptors on cancer cells: A still open question. J Clin Oncol 2007;/25:/1812-3.
14. Jelkmann W, Laugsch M. Problems in identifying functional erythropoietin receptors in cancer tissue. J Clin Oncol 2007;/ 25:/1627-8.
15. Sizer KC. Heat shock protein 70, erythropoietin, and cancer. J Clin Oncol 2007;/25:/4326.
16. Wojchowski DM, Gregory RC, Miller CP, Pandit AK, Pircher TJ. Signal transduction in the erythropoietin receptor system. Exp Cell Res 1999;/253:/143-56.
17. Ammarguellat F, Llovera M, Kelly PA, Goffin V. Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells. Biochem Biophys Res Commun 2001;/284:/1031-8.
18. Kjellén E, Sasaki Y, Kjellström J, Zackrisson B, Wennerberg J. Recombinant erythropoietin beta enhances growth of xenografted human squamous cell carcinoma of the head and neck after surgical trauma. Acta Otolaryngol 2006;/126:/ 545-547
19. Henriksson E, Baldetorp B, Borg A, Kjellen E, Akervall J, Wennerberg J, et al. p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck. Acta Oncol 2006;/45:/300-5.
20. Verdier F, Gomez S, Lacombe C, Mayeux P. Selected anti- Epo receptor antibodies predict Epo receptor expression. Blood 2006;/108:/1106.
21. Jones SS, D'Andrea AD, Haines LL, Wong GG. Human erythropoietin receptor: Cloning, expression, and biologic characterization. Blood 1990;/76:/31-5.
22. Wognum AW, Lansdorp PM, Humphries RK, Krystal G. Detection and isolation of the erythropoietin receptor using biotinylated erythropoietin. Blood 1990;/76:/697-705.
23. Verdier F,Walrafen P, Hubert N, Chrétien S, Gisselbrecht S, Lacombe C, et al. Proteasomes regulate the duration of erythropoietin receptor activation by controlling downregulation of cell surface receptors. J Biol Chem 2000;/275:/ 18375-18381
24. Buemi M, Galeano M, Sturiale A, Ientile R, Crisafulli C, Parisi A, et al. Recombinant human erythropoietin stimulates angiogenesis and healing of ischemic skin wounds. Shock 2004;/22:/169-73. (Pubitemid 40228196)
25. Haroon ZA, Amin K, Jiang X, Arcasoy MO. A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol 2003;/163:/993-1000.